HUP0101300A2 - Matrix metalloproteáz inhibitorok - Google Patents
Matrix metalloproteáz inhibitorokInfo
- Publication number
- HUP0101300A2 HUP0101300A2 HU0101300A HUP0101300A HUP0101300A2 HU P0101300 A2 HUP0101300 A2 HU P0101300A2 HU 0101300 A HU0101300 A HU 0101300A HU P0101300 A HUP0101300 A HU P0101300A HU P0101300 A2 HUP0101300 A2 HU P0101300A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- alkyl
- alkoxy
- general formula
- carbon atom
- Prior art date
Links
- 239000011159 matrix material Substances 0.000 title 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 title 1
- 229910052799 carbon Inorganic materials 0.000 abstract 5
- 229910052731 fluorine Inorganic materials 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- -1 indolyl- Chemical group 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 1
- XCUAIINAJCDIPM-XVFCMESISA-N N(4)-hydroxycytidine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=NO)C=C1 XCUAIINAJCDIPM-XVFCMESISA-N 0.000 abstract 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 abstract 1
- 125000004849 alkoxymethyl group Chemical group 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
- C07C259/18—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D317/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A találmány tárgya (I) általános képletű vegyületek vagygyógyszerészetileg elfogadható sóik vagy bármelyiknek a szolvátja - aképletben R1 jelentése H, OH, 1-4 szénatomos alkil-, 1-4 szénatomosalkoxi- vagy 2-4 szénatomos alkenil-, R2 jelentése 1-6 szénatomosalkil-, amely adott esetben valamely következő csoporttalszubsztituálva van: fluoratom, indolil-, imidazolil-, SO2(1-4szénatomos alkil)-, 5-7 szénatomos cikloalkil- vagy adott esetbenvédett OH, SH, CONH2, CO2H, NH2 vagy NHC(=NH)NH2 csoport, 5-7szénatomos cikloalkilcsoport, amely adott esetben 1-6 szénatomosalkilcsoporttal szubsztituálva van, vagy benzilcsoport, amely adottesetben szubsztituálva van egy adott esetben védett OH csoporttal, 1-6szénatomos alkoxi-, benzil-oxi- vagy benziltiocsoport, R3, R5 és R6jelentése egymástól függetlenül H vagy F, R4 jelentése CH3, Cl vagy F,X ; jelentése OH vagy HONH, Y jelentése egy vegyértékkötés vagy O, Zjelentése egy (a) általános képletű csoport - a képletben R10jelentése 1-4 szénatomos alkil-, 1-4 szénatomos alkoximetil-, hidroxi-(2-4 szénatomos alkil)-, karboxi(1-4 szénatomos alkil)- vagy (amino-vagy dimetilamino)-2-4 szénatomos alkil-, és R11 jelentése fenil-,naftil- vagy piridilcsoport, amelyek adott esetben max. háromszorosanhalogénatommal vagy metilcsoporttal szubsztituálva lehetnek, vagy egy(b) általános képletű csoport - a képletben Rl4 jelentése H, OH, CH3vagy halogénatom, Ar jelentése (c), (d) vagy (e) általános képletűcsoport, a képletekben A jelentése N vagy CR12, B jelentése N vagyCR13, azzal a megkötéssel, hogy A és B egyidejűleg nem lehet N, R7 ésR9 jelentése egymástól függetlenül H vagy F, R8, R12 és R13 jelentéseegymástól függetlenül H, CN, 1-6 szénatomos alkil-, hidroxi(1-6szénatomos alkil)-, hidroxi(1-6 szénatomos alkoxi)-, 1-6 szénatomosalkoxi-(1-6 szénatomos alkoxi)-, (amino- vagy dimetilamino)-1-6szénatomos alkil-, CONH2, OH, halogén, 1-6 szénatomos alkoxi-, (1-6szénatomos alkoxi)metil-, piperazinilkarbonil-, piperidinil-,C(NH2)=NOH vagy C(=NH)NHOH csoport, azzal a megkötéssel, hogy az R8,R12 és R13 közül legalább kettő jelentése H. A találmány vonatkoziktovábbá a fenti (I) általános képletű vegyületeket tartalmazógyógyszerkészítményekre, a vegyületek előállítási eljárására és azelőállításnál felhasználásra kerülő intermedierekre. Ó
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9800510.1A GB9800510D0 (en) | 1998-01-09 | 1998-01-09 | Therapeutic agents |
| GBGB9811843.3A GB9811843D0 (en) | 1998-06-02 | 1998-06-02 | Therapeutic agents |
| PCT/EP1998/008565 WO1999035124A1 (en) | 1998-01-09 | 1998-12-23 | Matrix metalloprotease inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0101300A2 true HUP0101300A2 (hu) | 2001-08-28 |
| HUP0101300A3 HUP0101300A3 (en) | 2002-11-28 |
Family
ID=26312925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0101300A HUP0101300A3 (en) | 1998-01-09 | 1998-12-23 | Matrix metalloprotease inhibitors |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US6350907B1 (hu) |
| EP (1) | EP1047665B1 (hu) |
| JP (1) | JP3621884B2 (hu) |
| KR (1) | KR100385662B1 (hu) |
| CN (1) | CN1284942A (hu) |
| AP (1) | AP1059A (hu) |
| AR (1) | AR014270A1 (hu) |
| AT (1) | ATE252547T1 (hu) |
| AU (1) | AU736511B2 (hu) |
| BG (1) | BG104575A (hu) |
| BR (1) | BR9813719A (hu) |
| CA (1) | CA2317604C (hu) |
| CO (1) | CO4990971A1 (hu) |
| CZ (1) | CZ20002459A3 (hu) |
| DE (1) | DE69819206T2 (hu) |
| DK (1) | DK1047665T3 (hu) |
| DZ (1) | DZ2701A1 (hu) |
| EA (1) | EA002971B1 (hu) |
| ES (1) | ES2209244T3 (hu) |
| HN (1) | HN1998000199A (hu) |
| HR (1) | HRP20000460A2 (hu) |
| HU (1) | HUP0101300A3 (hu) |
| IL (1) | IL136889A0 (hu) |
| IS (1) | IS5531A (hu) |
| MA (1) | MA26594A1 (hu) |
| NO (1) | NO20003506L (hu) |
| NZ (1) | NZ504683A (hu) |
| OA (1) | OA11435A (hu) |
| PA (1) | PA8466101A1 (hu) |
| PE (1) | PE20000176A1 (hu) |
| PL (1) | PL342763A1 (hu) |
| PT (1) | PT1047665E (hu) |
| SI (1) | SI1047665T1 (hu) |
| SK (1) | SK10112000A3 (hu) |
| TN (1) | TNSN99002A1 (hu) |
| TR (1) | TR200001909T2 (hu) |
| WO (1) | WO1999035124A1 (hu) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6352976B1 (en) | 1998-12-31 | 2002-03-05 | Aventis Pharmaceuticals Inc. | Selective inhibitors of MMP-12 |
| DK1140984T3 (da) * | 1998-12-31 | 2003-05-26 | Aventis Pharma Inc | Selektive inhibitorer af MMP-12 |
| JP2001055327A (ja) * | 1999-06-11 | 2001-02-27 | Fuji Chemical Industries Ltd | 新規なヒドロキサム酸誘導体を含む医薬 |
| US6452041B1 (en) | 2000-10-16 | 2002-09-17 | Pfizer Inc. | Olefination process to itaconate and succinate derivatives |
| GB0025310D0 (en) * | 2000-10-16 | 2000-11-29 | Pfizer Ltd | Process |
| BR0207307A (pt) * | 2001-02-16 | 2004-08-17 | Allelix Neuroscience Inc | Inibidores de glyt-1 |
| GB0126389D0 (en) * | 2001-11-02 | 2002-01-02 | Pfizer Ltd | Wafer |
| PA8578101A1 (es) * | 2002-08-13 | 2004-05-07 | Warner Lambert Co | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
| US20040138103A1 (en) * | 2002-11-07 | 2004-07-15 | Procyte Corporation | Compositions containing peptide copper complexes and metalloproteinase inhibitors and methods related thereto |
| WO2004060346A2 (en) | 2002-12-30 | 2004-07-22 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
| PL379863A1 (pl) * | 2003-08-23 | 2006-11-27 | Vernalis (R & D) Limited | Pochodne kwasu hydroksamowego jako inhibitory metaloproteinazy |
| EP2074428B1 (en) * | 2006-09-29 | 2015-07-01 | Roche Diagnostics GmbH | Assessing the risk of disease progression for a patient with rheumatoid arthritis |
| CN104788333B (zh) * | 2015-03-19 | 2017-03-22 | 中国医科大学 | 2‑取代‑9,10‑蒽醌类化合物、制备方法及其用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892112A (en) | 1990-11-21 | 1999-04-06 | Glycomed Incorporated | Process for preparing synthetic matrix metalloprotease inhibitors |
| GB9215665D0 (en) | 1992-07-23 | 1992-09-09 | British Bio Technology | Compounds |
| CA2149640A1 (en) | 1992-11-25 | 1994-06-09 | Kevin T. Chapman | Carboxy-peptidyl derivatives as antidegenerative active agents |
| CA2139128A1 (en) | 1993-04-27 | 1994-11-10 | Celltech Therapeutics Limited | Peptidyl derivatives as metalloproteinase inhibitors |
| GB9308695D0 (en) | 1993-04-27 | 1993-06-09 | Celltech Ltd | Peptidyl derivatives |
| GB9320660D0 (en) | 1993-10-07 | 1993-11-24 | British Bio Technology | Inhibition of cytokine production |
| US6037472A (en) * | 1993-11-04 | 2000-03-14 | Syntex (U.S.A.) Inc. | Matrix metalloprotease inhibitors |
| UA48121C2 (uk) | 1993-11-04 | 2002-08-15 | Сінтекс (С.Ш.А.) Інк. | Інгібітори матричних металопротеаз і фармацетична композиція на їх основі |
| CN1049651C (zh) | 1994-01-20 | 2000-02-23 | 英国生物技术药物有限公司 | 金属蛋白酶抑制剂 |
| DE69529100T2 (de) | 1994-01-22 | 2003-07-17 | British Biotech Pharm | Metalloproteinaseinhibitoren |
| WO1995032944A1 (en) | 1994-05-28 | 1995-12-07 | British Biotech Pharmaceuticals Limited | Succinyl hydroxamic acid, n-formyl-n-hydroxy amino carboxylic acid and succinic acid amide derivatives as metalloprotease inhibitors |
| US5461746A (en) * | 1995-01-17 | 1995-10-31 | Tdw Delaware, Inc. | Magnetic cleaning pig |
| GB9507799D0 (en) * | 1995-04-18 | 1995-05-31 | British Biotech Pharm | Metalloproteinase inhibitors |
| US5691381A (en) | 1995-04-18 | 1997-11-25 | The Dupont Merck Pharmaceutical Company | Hydroxamic and carbocyclic acids as metalloprotease inhibitors |
| US5994293A (en) | 1995-05-10 | 1999-11-30 | Darwin Discovery Ltd. | Peptidyl compounds and their therapeutic use |
| CA2217857A1 (en) | 1995-05-10 | 1996-11-14 | Darwin Discovery Limited | Peptide compounds which inhibit metalloproteinase and tnf liberation and their therapeutic uses |
| GB9513331D0 (en) | 1995-06-30 | 1995-09-06 | British Biotech Pharm | Matrix metalloproteinase inhibitors |
| US5917090A (en) * | 1995-06-30 | 1999-06-29 | British Biotech Pharmaceuticals Ltd. | Matrix metalloproteinase inhibitors |
| US5840974A (en) * | 1996-12-04 | 1998-11-24 | Britisch Biotech Pharmaceuticals, Ltd. | Metalloproteinase inhibitors |
-
1998
- 1998-12-23 DK DK98966429T patent/DK1047665T3/da active
- 1998-12-23 CA CA002317604A patent/CA2317604C/en not_active Expired - Fee Related
- 1998-12-23 SI SI9830577T patent/SI1047665T1/xx unknown
- 1998-12-23 DE DE69819206T patent/DE69819206T2/de not_active Expired - Fee Related
- 1998-12-23 CZ CZ20002459A patent/CZ20002459A3/cs unknown
- 1998-12-23 TR TR2000/01909T patent/TR200001909T2/xx unknown
- 1998-12-23 HU HU0101300A patent/HUP0101300A3/hu unknown
- 1998-12-23 EP EP98966429A patent/EP1047665B1/en not_active Expired - Lifetime
- 1998-12-23 KR KR10-2000-7007583A patent/KR100385662B1/ko not_active IP Right Cessation
- 1998-12-23 ES ES98966429T patent/ES2209244T3/es not_active Expired - Lifetime
- 1998-12-23 PL PL98342763A patent/PL342763A1/xx unknown
- 1998-12-23 JP JP2000527526A patent/JP3621884B2/ja not_active Expired - Fee Related
- 1998-12-23 NZ NZ504683A patent/NZ504683A/en unknown
- 1998-12-23 SK SK1011-2000A patent/SK10112000A3/sk unknown
- 1998-12-23 CN CN98812936A patent/CN1284942A/zh active Pending
- 1998-12-23 EA EA200000628A patent/EA002971B1/ru not_active IP Right Cessation
- 1998-12-23 AU AU22776/99A patent/AU736511B2/en not_active Ceased
- 1998-12-23 BR BR9813719-0A patent/BR9813719A/pt not_active Application Discontinuation
- 1998-12-23 WO PCT/EP1998/008565 patent/WO1999035124A1/en active IP Right Grant
- 1998-12-23 IL IL13688998A patent/IL136889A0/xx unknown
- 1998-12-23 AT AT98966429T patent/ATE252547T1/de not_active IP Right Cessation
- 1998-12-23 PT PT98966429T patent/PT1047665E/pt unknown
- 1998-12-30 HN HN1998000199A patent/HN1998000199A/es unknown
- 1998-12-30 CO CO98077587A patent/CO4990971A1/es unknown
-
1999
- 1999-01-04 PE PE1999000004A patent/PE20000176A1/es not_active Application Discontinuation
- 1999-01-04 PA PA19998466101A patent/PA8466101A1/es unknown
- 1999-01-06 MA MA25419A patent/MA26594A1/fr unknown
- 1999-01-06 DZ DZ990002A patent/DZ2701A1/xx active
- 1999-01-06 TN TNTNSN99002A patent/TNSN99002A1/fr unknown
- 1999-01-07 AR ARP990100048A patent/AR014270A1/es not_active Application Discontinuation
- 1999-01-07 AP APAP/P/1999/001436A patent/AP1059A/en active
-
2000
- 2000-04-11 US US09/546,756 patent/US6350907B1/en not_active Expired - Fee Related
- 2000-06-13 IS IS5531A patent/IS5531A/is unknown
- 2000-06-23 OA OA1200000188A patent/OA11435A/en unknown
- 2000-07-04 BG BG104575A patent/BG104575A/xx unknown
- 2000-07-07 NO NO20003506A patent/NO20003506L/no not_active Application Discontinuation
- 2000-07-07 HR HR20000460A patent/HRP20000460A2/hr not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0101300A2 (hu) | Matrix metalloproteáz inhibitorok | |
| HUP0301857A2 (hu) | 3(5)-Ureido-pirazol-származékok, eljárás elżállításukra alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
| CA2155673A1 (en) | N-alkyl-2-substituted atp analogues | |
| CA2392973A1 (en) | Benzoimidazole derivatives useful as antiproliferative agents | |
| MY139357A (en) | Novel benzoimidazole derivatives useful as antiproliferative agents | |
| PL315636A1 (en) | Cosmetic or pharmaceutic compositions containing magnipherine or its derivatives | |
| HUP0201789A2 (hu) | A légzőrendszerre ható szinciciális vírus replikációját gátló vegyületek | |
| DE69831868D1 (en) | Antithrombosemittel | |
| AP2001002241A0 (en) | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents. | |
| HUP0400636A2 (hu) | Azetidinszármazékokat tartalmazó gyógyszerkészítmények, új azetidinszármazékok és előállításuk | |
| DE69923849D1 (de) | Quinolin-2-on-derivate verwendbar als antikrebsmittel | |
| GEP20074208B (en) | Substituted amides active at the cannabinoid-1 receptor | |
| MXPA04000577A (es) | Derivados de dolastatina 10. | |
| MY141661A (en) | 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
| HUP9901296A2 (hu) | NMDA receptor antagonista hatású szubsztituált piridinszármazékok, valamint ezeket a vegyületeket tartalmazó gyógyszerkészítmények | |
| CA2304713A1 (en) | Biphenyl-5-alkanoic acid derivatives and use thereof | |
| IL94433A0 (en) | Aminophenol derivatives,their preparation and pharmaceutical compositions containing them | |
| MX9706647A (es) | Composiciones farmaceuticas que comprenden inhibidores de oxidasa b de monoamina. | |
| HUP9801946A2 (hu) | 5-HT-felvétel-inhibitorból és szelektív 5-H1A-antagonistából álló kombinációs gyógyászati készítmény és eljárás előállítására | |
| MY139612A (en) | Benzoxazine derivatives as 5-th6 modulators and uses thereof | |
| MY139027A (en) | N-acylamino benzyl ether derivatives | |
| CA2438509A1 (en) | Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria | |
| EP1404652A4 (en) | NEW ALKALOID DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | |
| BG105334A (en) | Tricyclic delta 3-piperidines as pharmaceuticals | |
| HUP9802348A2 (hu) | 2-Fenil-3-aroil-benzotiofének alkalmazása plazminogén aktivátor inhibitor-1 gátló hatású gyógyszerkészítmények előállítására |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |